1
|
Ramirez-Fort MK, Kardoust-Parizi M, Flannigan R, Bach P, Koch N, Gilman C, Suarez P, Fort DV, McClelland S, Lange CS, Mulhall JP, Fort M, Schlegel PN. Preservation of male fertility in patients undergoing pelvic irradiation. Rep Pract Oncol Radiother 2024; 28:835-845. [PMID: 38515820 PMCID: PMC10954274 DOI: 10.5603/rpor.98731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Accepted: 12/04/2023] [Indexed: 03/23/2024] Open
Abstract
As the number of cancer survivors increases, so does the demand for preserving male fertility after radiation. It is important for healthcare providers to understand the pathophysiology of radiation-induced testicular injury, the techniques of fertility preservation both before and during radiation, and their role in counseling patients on the risks to their fertility and the means of mitigating these risks. Impaired spermatogenesis is a known testicular toxicity of radiation in both the acute and the late settings, as rapidly dividing spermatogonial germ cells are exquisitely sensitive to irradiation. The threshold for spermatogonial injury and subsequent impairment in spermatogenesis is ~ 0.1 Gy and the severity of gonadal injury is highly dose-dependent. Total doses < 4 Gy may allow for recovery of spermatogenesis and fertility potential, but with larger doses, recovery may be protracted or impossible. All patients undergoing gonadotoxic radiation therapy should be counseled on the possibility of future infertility, offered the opportunity for semen cryopreservation, and offered referral to a fertility specialist. In addition to this, every effort should be made to shield the testes (if not expected to contain tumor) during therapy.
Collapse
Affiliation(s)
- Marigdalia K. Ramirez-Fort
- Life Sciences & BioDefense, BioFort Corp, Guaynabo, Puerto Rico, United States
- Department of Urology, Weill Cornell Medicine, New York, NY, United States
| | - Mehdi Kardoust-Parizi
- Department of Urology, Medical University of Vienna, Vienna, Austria
- Department of Urology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - Ryan Flannigan
- Department of Urology, Weill Cornell Medicine, New York, NY, United States
| | - Phil Bach
- Department of Urology, Weill Cornell Medicine, New York, NY, United States
| | - Nicholas Koch
- Department of Medical Physics, CONE Health, Greensboro, NC, United States
| | - Casey Gilman
- Life Sciences & BioDefense, BioFort Corp, Guaynabo, Puerto Rico, United States
- Department of Psychiatry, Mayo Clinic College of Medicine and Science, Rochester, MN, United States
| | - Paula Suarez
- Life Sciences & BioDefense, BioFort Corp, Guaynabo, Puerto Rico, United States
- Department of Psychiatry, Mayo Clinic College of Medicine and Science, Rochester, MN, United States
| | - Digna V. Fort
- Life Sciences & BioDefense, BioFort Corp, Guaynabo, Puerto Rico, United States
| | - Shearwood McClelland
- Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana, United States
| | - Christopher S. Lange
- Life Sciences & BioDefense, BioFort Corp, Guaynabo, Puerto Rico, United States
- Department of Radiation Oncology, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
| | - John P. Mulhall
- Department of Sexual and Reproductive Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States
| | - Migdalia Fort
- Life Sciences & BioDefense, BioFort Corp, Guaynabo, Puerto Rico, United States
| | - Peter N. Schlegel
- Department of Urology, Weill Cornell Medicine, New York, NY, United States
| |
Collapse
|
2
|
Pediatric and Adolescent Oncofertility in Male Patients-From Alpha to Omega. Genes (Basel) 2021; 12:genes12050701. [PMID: 34066795 PMCID: PMC8150386 DOI: 10.3390/genes12050701] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 05/02/2021] [Accepted: 05/04/2021] [Indexed: 01/15/2023] Open
Abstract
This article reviews the latest information about preserving reproductive potential that can offer enhanced prospects for future conception in the pediatric male population with cancer, whose fertility is threatened because of the gonadotoxic effects of chemotherapy and radiation. An estimated 400,000 children and adolescents aged 0–19 years will be diagnosed with cancer each year. Fertility is compromised in one-third of adult male survivors of childhood cancer. We present the latest approaches and techniques for fertility preservation, starting with fertility preservation counselling, a clinical practice guideline used around the world and finishing with recent advances in basic science and translational research. Improving strategies for the maturation of germ cells in vitro combined with new molecular techniques for gene editing could be the next scientific keystone to eradicate genetic diseases such as cancer related mutations in the offspring of cancer survivors.
Collapse
|
3
|
Mintziori G, Lambrinoudaki I, Ceausu I, Depypere H, Tamer Erel C, Pérez-López FR, Schenck-Gustafsson K, van der Schouw YT, Simoncini T, Tremollieres F, Tarlatzis BC, Rees M, Goulis DG. EMAS position statement: Fertility preservation. Maturitas 2014; 77:85-9. [DOI: 10.1016/j.maturitas.2013.10.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|